证券代码：301206 证券简称：三元生物 公告编号：2025-090 山东三元生物科技股份有限公司 关于使用暂时闲置超募资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2025 年 1 月 24 日召开了第五届董事会第五次会议和第五届监事会第五次会议，于 2025 年 2 月 10 日召开了 2025 年第二次临时股东大会，上述会议审议通过了《关于使用暂时 闲置超募资金进行现金管理的议案》。同意公司在不影响日常生产经营和保证超 募资金安全使用的前提下，拟使用不超过 190,000 万元人民币暂时闲置超募资金 进行现金管理。使用期限自公司 2025 年第二次临时股东大会会议审议通过之日 起 12 个月内有效，在上述投资额度和使用期限内资金可滚动使用。公司授权管 理层在上述额度范围及期限内行使投资决策、签署相关文件等事宜，具体事项由 公司财务部负责组织实施。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于使用暂时闲置超 ...

证券日报网讯12月22日，三元生物（301206）在互动平台回答投资者提问时表示，截至12月19日公司在 册股东共15452户。 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-089 山东三元生物科技股份有限公司 2025 年前三季度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重点内容提示： 1、山东三元生物科技股份有限公司（以下简称"公司"）回购专用证券账 户中的股份 2,325,700 股不参与本次权益分派。公司 2025 年前三季度权益分派 方案为：以公司现有总股本 202,325,700 股剔除已回购股份 2,325,700 股后的总股 本 200,000,000 股为基数，向全体股东每 10 股派 5.0 元（含税），共计派发 100,000,000 元，不送红股，不以资本公积金转增股本，剩余未分配利润结转下 一年度。 2、本次权益分派实施后，根据股票市值不变原则，实施权益分派前后公司 总股本保持不变，现金红利总金额分摊到每一股的比例将减小，因此计算除权除 息价格时，按公司总股本（含回购股份）折算的每股现金红利（含税）=现金红 利总额÷总股本（含回购股份）= [（202,325,700 股-2,325,700 股）÷10 股×5.0 元/ ...

证券日报网讯 12月10日，三元生物在互动平台回答投资者提问时表示，分红预案实施时间将在相关事 项依法办理并符合监管要求后由公司及时披露，请以正式公告为准。 （文章来源：证券日报） ...

证券日报网讯12月1日，三元生物（301206）在互动平台回答投资者提问时表示，截至11月30日公司在 册股东共16094户。 ...

Core Viewpoint - The company, Shandong Sanyuan Biotechnology Co., Ltd., specializes in the research, production, and sales of erythritol and its compound products, benefiting from trends in sugar alternatives, synthetic biology, and green energy [2][7]. Group 1: Company Overview - The company was established on January 26, 2007, and went public on February 10, 2022 [7]. - Main business revenue composition includes sugar alcohols (88.22%), functional sugars (8.59%), and others (2.93%) [7]. - The company is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating strong innovation capabilities and market share [2]. Group 2: Financial Performance - For the period from January to September 2025, the company reported revenue of 476 million yuan, a year-on-year decrease of 7.54%, and a net profit attributable to shareholders of 67.4 million yuan, down 16.80% year-on-year [7]. - Cumulative cash dividends since the company's A-share listing amount to 608 million yuan, with 473 million yuan distributed over the past three years [8]. Group 3: Market Position and Trends - The company benefits from a 69.27% share of overseas revenue, aided by the depreciation of the Renminbi [3]. - The company is involved in distributed photovoltaic power generation projects, which reduce reliance on traditional energy sources and lower greenhouse gas emissions [2]. Group 4: Stock Performance - As of December 1, the stock price increased by 0.29%, with a trading volume of 22.05 million yuan and a market capitalization of 5.606 billion yuan [1]. - The average trading cost of the stock is 29.42 yuan, with a current support level at 27.27 yuan [6].

Core Viewpoint - The company, Shandong Sanyuan Biotechnology Co., Ltd., is engaged in the research, production, and sales of erythritol and its compound products, benefiting from trends in sugar alternatives, synthetic biology, and green energy [2][7]. Group 1: Company Overview - The main products of the company include erythritol and compound sugars, with a revenue composition of 88.22% from sugar alcohols, 8.59% from functional sugars, 2.93% from other categories, and 0.26% from glycosides [7]. - The company was established on January 26, 2007, and went public on February 10, 2022 [7]. - As of November 20, the number of shareholders increased by 5.13% to 16,300, with an average of 7,977 circulating shares per person, a decrease of 4.88% [7]. Group 2: Financial Performance - For the period from January to September 2025, the company reported a revenue of 476 million yuan, a year-on-year decrease of 7.54%, and a net profit attributable to shareholders of 67.4 million yuan, down 16.80% year-on-year [7]. - The company has distributed a total of 608 million yuan in dividends since its A-share listing, with 473 million yuan distributed over the past three years [8]. Group 3: Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for companies excelling in niche markets and possessing strong innovation capabilities [2]. - The company benefits from a significant overseas revenue share of 69.27%, aided by the depreciation of the Chinese yuan [3]. Group 4: Recent Market Activity - On November 28, the company's stock price increased by 0.11%, with a trading volume of 28.5 million yuan and a turnover rate of 0.79%, resulting in a total market capitalization of 5.59 billion yuan [1]. - The stock's average trading cost is 29.43 yuan, with the current price near a support level of 27.27 yuan [6].

Core Viewpoint - Sanwei Biological announced that its erythritol exports to the EU market have been significantly impacted due to the highest applicable tax rate in the EU anti-dumping investigation [2] Group 1: Business Adjustments - In response to the challenges posed by the EU anti-dumping investigation, the company has adjusted its existing business model [2] - The company has introduced a blended product with erythritol content below 90% to EU customers, which has gradually increased customer acceptance and shipment volume [2] - The company is constructing a corn processing production line to address the high prices of alternative starch and is preparing for a review in compliance with EU trade rules to protect its legal rights [2]

Core Viewpoint - San Yuan Bio announced on November 25 that it will strictly adhere to compliance principles in fund usage, aiming to enhance efficiency and maximize economic benefits [2] Group 1: Fund Utilization - The company emphasizes the importance of compliance in fund usage to improve efficiency and economic returns [2] - San Yuan Bio is committed to maximizing economic benefits through effective fund management [2] Group 2: Investment and Mergers - A dedicated team has been established to focus on external investments and mergers, although no specific public results have been achieved yet [2] - The company plans to leverage the capital market for strategic partnerships to expand its performance scale and enhance profitability [2] Group 3: Shareholder Returns - San Yuan Bio aims to better reward shareholders through improved performance and profitability [2]

Core Viewpoint - The announcement from Sanwei Biological highlights the significant impact of the U.S. Department of Commerce's preliminary ruling on the anti-dumping investigation of erythritol, which imposes a preliminary tax rate of 450.64% on the company, creating barriers for exports to the U.S. market [2] Group 1 - On July 15, 2025, the U.S. Department of Commerce announced the preliminary ruling in the anti-dumping investigation, listing the company as a mandatory respondent [2] - The final ruling, originally scheduled for December 1, 2025, is expected to be delayed due to the recent U.S. government shutdown [2] - The preliminary ruling has created a significant obstacle for Chinese erythritol exports to the U.S., leading to a temporary tightening of supply in the U.S. market [2] Group 2 - Despite the challenges in the U.S. market, demand in North America remains, and imports of the company's products from neighboring countries like Canada and Mexico have gradually increased [2] - The company's third-quarter sales revenue showed a year-on-year increase, although the proportion of overseas revenue slightly decreased compared to the first half of the year [2] - Export growth to other countries and regions has partially offset the decline in the U.S. market [2]